Physician profile
Arun Agarwal
NPI 1073590493
$187,293.62
in general payments reported to CMS, 2019-2025
49 companies · $40K in 2025
The $40K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,472 · 2021: $14K · 2022: $39K · 2023: $35K · 2024: $38K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Food and Beverage: $5,993 · Travel and Lodging: $2,846 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,590.00 |
| Food and Beverage | $5,992.96 |
| Travel and Lodging | $2,846.42 |
| Education | $159.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $139,973.24 | 2019-2025 | Tezspire, Fasenra |
| Grifols USA, LLC | $26,834.57 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,482.85 | 2019-2024 | Jardiance |
| Genentech USA, INC. | $5,185.65 | 2019-2021 | |
| Amgen INC. | $3,173.01 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,271.32 | 2019-2022 | |
| Grifols Shared Services North America, INC. | $660.00 | 2023 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $431.31 | 2020-2022 | |
| Genzyme Corporation | $373.24 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $330.93 | 2019-2023 | |
| Insmed, INC. | $329.27 | 2020-2025 | Brinsupri, Arikayce |
| Janssen Pharmaceuticals, INC | $291.08 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $212.67 | 2019-2022 | |
| Pulmonx Corporation | $164.04 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Verona Pharma, INC. | $124.53 | 2025 | Ohtuvayre |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.